A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

CONCLUSION: The primary endpoint was met, with durvalumab plus tremelimumab/danvatirsen generally well tolerated in patients with relapsed/refractory DLBCL; however, antitumor activity was limited.PMID:33632668 | DOI:10.1016/j.clml.2020.12.012

Source: Clinical Lymphoma and Myeloma - February 26, 2021 Category: Cancer & Oncology Authors: Vincent Ribrag Seung Tae Lee David Rizzieri Martin J S Dyer Luis Fayad Razelle Kurzrock Leslie Andritsos Reda Bouabdallah Amjad Hayat Larry Bacon Yu Jiang Kowser Miah Bruno Delafont Oday Hamid Stephanie Anyanwu Pablo Martinez Brian Hess Source Type: research